Vasil'eva T V, Raskidaĭlo A S, Arutcheva A A, Okropiridze G G, Petrakov A A, Urazgil'deev Z I, Kovalenko T M
Antibiot Khimioter. 1993 Aug-Sep;38(8-9):61-3.
A clinico-laboratory study of miramistin, a new antiseptic was carried out. Susceptibility of 236 bacterial strains to miramistin was tested and its therapeutic efficacy was followed up in 10 patients with purulent inflammatory affections of the locomotor system treated locally. After an 18-hour exposure of the strains to a 0.01 per cent solution of miramistin only 9.3 per cent of the isolates (mainly staphylococci) remained viable. Gram-negative cocci died in 6 hours and streptococci died in 1 hour. The local treatment of the wounds on the average for 14 days provided lower dissemination of the pathological foci. In the majority of the patients there was stated primary union of the wounds. On the whole, the results were good in 7 patients, satisfactory in 2 patients and unsatisfactory in 1 patient. No side effects were recorded. Miramistin may be recommended as an antiseptic for the local treatment of infected wounds in traumatologic and orthopedic patients.
对一种新型防腐剂米拉美斯汀进行了临床实验室研究。检测了236株细菌对米拉美斯汀的敏感性，并对10例接受局部治疗的运动系统化脓性炎症患者的治疗效果进行了跟踪。将菌株暴露于0.01%的米拉美斯汀溶液中18小时后，仅9.3%的分离株（主要是葡萄球菌）仍存活。革兰氏阴性球菌在6小时内死亡，链球菌在1小时内死亡。伤口平均局部治疗14天，病理病灶的扩散程度较低。大多数患者伤口一期愈合。总体而言，7例患者效果良好，2例患者效果满意，1例患者效果不满意。未记录到副作用。米拉美斯汀可推荐作为创伤科和骨科患者感染伤口局部治疗的防腐剂。
